"Nvidia's Soaring Stock and Strategic AI Partnerships: A Look at the Chip King's Explosive Growth"

Nvidia's stock surged 24% as it continues to make strides in AI and life sciences, with partnerships with Meta, Recursion, and Amgen. The company's BioNeMo platform and collaborations with Recursion and Amgen demonstrate its leading role in integrating AI within drug discovery. Meanwhile, Prime Medicine's stock saw a 20% tumble following a downgrade by Stifel, reflecting greater investor interest in CRISPR-based gene editing technologies. Allakos announced a workforce reduction and restructuring after its lirentelimab missed endpoints, while Bullfrog AI's shares nearly doubled after early results from its collaboration with the Lieber Institute for Brain Development showed promising insights into psychiatric disorders.